Evaxion Biotech (EVAX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech A/S, a clinical-stage company leveraging AI to create personalized cancer vaccines, is set to present significant one-year clinical efficacy data from their Phase 2 study of EVX-01 at the prestigious ESMO Congress 2024. EVX-01 is a peptide-based personalized therapy for advanced melanoma, currently in trials in combination with KEYTRUDA. This milestone underscores Evaxion’s commitment to advancing novel and targeted treatment options for patients with unmet medical needs.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.